Leukemia, Myelomonocytic, Chronic
"Leukemia, Myelomonocytic, Chronic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.
Descriptor ID |
D015477
|
MeSH Number(s) |
C04.557.337.539.522 C15.378.190.615.510
|
Concept/Terms |
Leukemia, Myelomonocytic, Chronic- Leukemia, Myelomonocytic, Chronic
- Myelomonocytic Leukemia, Chronic
- Chronic Myelomonocytic Leukemia
- Chronic Myelomonocytic Leukemias
- Leukemia, Chronic Myelomonocytic
- Leukemias, Chronic Myelomonocytic
- Myelomonocytic Leukemias, Chronic
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelomonocytic, Chronic".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelomonocytic, Chronic".
This graph shows the total number of publications written about "Leukemia, Myelomonocytic, Chronic" by people in this website by year, and whether "Leukemia, Myelomonocytic, Chronic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 1 | 0 | 1 |
2011 | 0 | 1 | 1 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2017 | 4 | 0 | 4 |
2019 | 3 | 0 | 3 |
2020 | 2 | 0 | 2 |
2021 | 2 | 0 | 2 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, Myelomonocytic, Chronic" by people in Profiles.
-
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024 Jan; 11(1):e15-e26.
-
Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. Am J Hematol. 2021 09 01; 96(9):E327-E330.
-
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv. 2021 04 27; 5(8):2264-2271.
-
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 08 06; 136(6):674-683.
-
Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. Int J Lab Hematol. 2020 Aug; 42(4):418-422.
-
How I investigate chronic myelomonocytic leukemia. Int J Lab Hematol. 2020 Apr; 42(2):101-108.
-
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019 10; 104(10):1935-1949.
-
Update on the pathologic diagnosis of chronic myelomonocytic leukemia. Mod Pathol. 2019 06; 32(6):732-740.
-
Genomic determinants of chronic myelomonocytic leukemia. Leukemia. 2017 12; 31(12):2815-2823.
-
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia. Mod Pathol. 2017 09; 30(9):1213-1222.